ondansetron has been researched along with Breast Cancer in 82 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We decided to evaluate the efficacy of olanzapine with the real-life practice antiemetic drugs ondansetron and dexamethasone, in prevention of CINV resulting from doxorubicin plus cyclophosphamide regimen in early-stage breast cancer patients." | 9.30 | A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. ( Laohavinij, S; Maneechavakajorn, J; Maneenil, K; Nipondhkit, W; Payapwattanawong, S; Sa-Nguansai, S; Tienchaiananda, P, 2019) |
| "Breast cancer patients in a phase III double-blind, placebo-controlled trial were randomized to antiemetic regimens including ondansetron and dexamethasone, or aprepitant, ondansetron, and dexamethasone." | 9.15 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. ( Carides, AD; Street, JC; Warr, DG, 2011) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 9.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients." | 9.14 | A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. ( Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B, 2009) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 9.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide +/- doxorubicin or epirubicin." | 9.11 | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. ( Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG, 2005) |
| "In this study we evaluated the efficacy of electro-acupoint stimulation, ondansetron versus placebo for the prevention of postoperative nausea and vomiting (PONV)." | 9.11 | A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. ( Gan, TJ; Georgiade, G; Jiao, KR; Zenn, M, 2004) |
| "Ondansetron 4 mg or dexamethasone 4 mg are equally effective in the prevention of postoperative nausea and vomiting following breast surgery." | 9.10 | Dexamethasone is as effective as ondansetron for the prevention of postoperative nausea and vomiting following breast surgery. ( Gupta, A; Liljegren, G; Lövqvist, A; Thörn, SE; Wattwil, L; Wattwil, M, 2003) |
| " Our hypothesis is that coinduction with clonidine reduces the incidence of PONV in adult patients undergoing breast cancer surgery." | 9.10 | Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery. ( Bergendahl, HT; Eksborg, S; Lönnqvist, PA; Muhrbeck, O; Oddby-Muhrbeck, E, 2002) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 9.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 9.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 9.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 9.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 9.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 9.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "A total of 54 breast cancer patients receiving high-dose cyclophosphamide, cisplatin and carmustine were treated prospectively in four sequential cohorts." | 9.08 | Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ( Berry, D; Cavanaugh, C; Fehdrau, R; Gilbert, CJ; Hussein, A; McKinstry, C; Peters, WP; Petros, WP; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "A group of 48 patients with breast cancer were randomized in a double-blind fashion to receive either (1) granisetron as a 0." | 9.08 | Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. ( Bolwell, B; Boparai, N; Jones, E; Kalaycio, M; Mendez, Z; Overmoyer, B; Pohlman, B, 1998) |
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 9.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 9.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 9.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 9.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 9.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 9.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 9.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients." | 9.07 | Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. ( Campora, E; Cetto, GL; Fosser, V; Mammoliti, S; Marangolo, M; Oliva, C; Rosso, R, 1991) |
| " In this randomized, double-blind, placebo-controlled study, we evaluated the effect of serotonin S3 receptor blockade with ondansetron (GR 38032F) on the prevention of nausea and vomiting induced by cyclophosphamide-containing chemotherapy." | 9.06 | Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffman, IS, 1990) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "The patient completed the remainder of the radiation treatment with no further emesis and minimal nausea, representing the first documented success of granisetron and aprepitant for RINV after failure on ondansetron." | 7.81 | Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report. ( Chow, E; DeAngelis, C; Hunyh, L; McDonald, R; Pasetka, M; Raman, S; Rowbottom, L, 2015) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 7.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 7.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 7.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "We investigated the prophylactic antiemetic effect of added low-dose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer." | 7.69 | Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. ( Borgeat, A; Forni, M; Suter, PM; Wilder-Smith, O, 1994) |
| "as prophylaxis in breast cancer patients regimens was studied." | 6.71 | Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. ( Coop, AJ; Dempsey, CL; Eberhardt, DR; Farley, PA; O'Briant, S; Shillington, A, 2004) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 6.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "Ondansetron alone was not adequate to provide sustained control of CT-induced nausea and vomiting over the entire 5-day study period." | 6.69 | An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. ( Cohen, L; Davidson, T; Dix, SP; Joyce, R; Lynn, M; Miyahara, T; Osowski, CL; Sexauer, MC; Wingard, JR; Yeager, A, 1998) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 6.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| "A total of 259 chemotherapy-naive breast cancer patients treated with a 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen were randomly assigned to ondansetron (OND) 8 mg tablet or alizapride (ALI) 150 mg intravenous (i." | 6.68 | Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group. ( Bonneterre, J; Clavel, M; d'Allens, H; Paillarse, JM, 1995) |
| " Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide before chemotherapy, followed by oral dosing with 8 mg ondansetron or 20 mg metoclopramide 3 times daily for 5 days." | 6.67 | Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. ( Cassidy, J; Coleman, R; Hunter, E; Kaye, S; Kerr, D; Khanna, S; McQuade, B; Smyth, J; Soukop, M; Stewart, A, 1992) |
| " We decided to evaluate the efficacy of olanzapine with the real-life practice antiemetic drugs ondansetron and dexamethasone, in prevention of CINV resulting from doxorubicin plus cyclophosphamide regimen in early-stage breast cancer patients." | 5.30 | A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. ( Laohavinij, S; Maneechavakajorn, J; Maneenil, K; Nipondhkit, W; Payapwattanawong, S; Sa-Nguansai, S; Tienchaiananda, P, 2019) |
| "Ondansetron was given intravenously at a dose of 8 mg, and venous blood samples were drawn at 0, 20, 60 and 120 min." | 5.29 | Ondansetron does not stimulate prolactin release in breast cancer patients. ( Barni, S; Cazzaniga, M; Lissoni, P; Mainini, E; Rovelli, F; Tancini, G, 1994) |
| "Ginger (500 mg) twice daily was safe, but conferred no additional benefit in terms of reducing nausea severity in breast cancer patients receiving AC and ondansetron and dexamethasone for CINV prophylaxis." | 5.24 | Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. ( Akewanlop, C; Chantharasamee, J; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Soparattanapaisarn, N; Srimuninnimit, V; Techawathanawanna, S; Thamlikitkul, L, 2017) |
| "Despite the addition of aprepitant, extended-duration dexamethasone and olanzapine, patients at high risk for CINV due to personal risk factors failed to achieve good nausea control." | 5.22 | Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors. ( Bouganim, N; Clemons, M; Dranitsaris, G; Mazzarello, S; Smith, S; Vandermeer, L, 2016) |
| " The objective of this study was to establish the overall complete response (CR; no emesis or use of rescue medication 0-120 h after chemotherapy) with either ondansetron- or palonosetron-containing antiemetic regimens in patients receiving highly emetogenic chemotherapy (HEC)." | 5.17 | Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. ( Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R, 2013) |
| "Breast cancer patients in a phase III double-blind, placebo-controlled trial were randomized to antiemetic regimens including ondansetron and dexamethasone, or aprepitant, ondansetron, and dexamethasone." | 5.15 | Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. ( Carides, AD; Street, JC; Warr, DG, 2011) |
| "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients." | 5.14 | A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. ( Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B, 2009) |
| "The purpose of this phase III trial was to evaluate the efficacy and safety of regimens containing casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting during the first cycle in patients receiving moderately emetogenic chemotherapy (MEC)." | 5.14 | Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. ( Apornwirat, W; Aziz, Z; Grunberg, SM; Guckert, M; Herrstedt, J; Levin, J; Ranganathan, S; Roila, F; Russo, MW; Shaharyar, A; Van Belle, S, 2009) |
| "The purpose of this article is to assess the comparative antiemetic efficacy of prochlorperazine, ondansetron, and dexamethasone in the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) after moderately high to highly emetogenic chemotherapy." | 5.11 | Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. ( Amamoo, MA; Bernard, S; Goodin, S; Kane, M; Laliberte, K; Lindley, C; McCune, J; Pham, T; Schell, M; Shord, S; Socinski, MA; Yowell, S, 2005) |
| "Eligible breast cancer patients were naive to emetogenic chemotherapy and treated with cyclophosphamide +/- doxorubicin or epirubicin." | 5.11 | Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. ( Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG, 2005) |
| "In this study we evaluated the efficacy of electro-acupoint stimulation, ondansetron versus placebo for the prevention of postoperative nausea and vomiting (PONV)." | 5.11 | A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting. ( Gan, TJ; Georgiade, G; Jiao, KR; Zenn, M, 2004) |
| " Our hypothesis is that coinduction with clonidine reduces the incidence of PONV in adult patients undergoing breast cancer surgery." | 5.10 | Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery. ( Bergendahl, HT; Eksborg, S; Lönnqvist, PA; Muhrbeck, O; Oddby-Muhrbeck, E, 2002) |
| "Ondansetron 4 mg or dexamethasone 4 mg are equally effective in the prevention of postoperative nausea and vomiting following breast surgery." | 5.10 | Dexamethasone is as effective as ondansetron for the prevention of postoperative nausea and vomiting following breast surgery. ( Gupta, A; Liljegren, G; Lövqvist, A; Thörn, SE; Wattwil, L; Wattwil, M, 2003) |
| "The objective of this double blind parallel-group multicentre study was to compare the efficacy and safety of the combination ondansetron + methylprednisolone + lorazepam (O + M + L) in the prevention of emesis induced by chemotherapy with cyclophosphamide or adriamycin ." | 5.09 | [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. ( Bonneterre, J; Harousseau, JL; Hedouin, M; Ouvry, J; Zittoun, R, 2000) |
| "We aimed to evaluate the antiemetic efficacy, safety, and clinical utility of prophylactic ondansetron administered at the end of the surgery for the prevention of postoperative nausea and vomiting (PONV) in a homogenous population of 54 women undergoing modified radical mastectomy (MRM)." | 5.09 | The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy. ( Kannan, TR; Kathirvel, S; Mohan, V; Sadhasivam, S; Saxena, A; Trikha, A, 1999) |
| "The aim of our single-center, prospective, randomized, open study was to evaluate the antiemetic efficacy and tolerability of a regimen based on a single oral dose of ondansetron 8 mg in comparison with a metoclopramide-based regimen, for prevention of acute FAC (fluorouracil, doxorubicin and cyclophosphamide) chemotherapy-induced emesis." | 5.09 | High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. ( Bosnjak, SM; Mitrovi, LB; Nesković-Konstantinović, ZB; Radulović, SS; Susnjar, S, 2000) |
| "A total of 54 breast cancer patients receiving high-dose cyclophosphamide, cisplatin and carmustine were treated prospectively in four sequential cohorts." | 5.08 | Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer. ( Berry, D; Cavanaugh, C; Fehdrau, R; Gilbert, CJ; Hussein, A; McKinstry, C; Peters, WP; Petros, WP; Ross, M; Rubin, P; Vredenburgh, J, 1998) |
| "Successful control of vomiting was achieved in the first 24 hours, in 74% of the cycles containing cisplatin and 82% of the cycles without cisplatin, if ondansetron was used." | 5.08 | Ondansetron in chemotherapy-induced emesis. Our experience. ( Bandiera, AF; Fiorelli, C; Framarino dei Malatesta, M; Marzetti, L; Toccaceli Blasi, MR; Veneziano, M; Yacoub, M, 1995) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 5.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 5.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "This study was undertaken to further determine the clinical value of ondansetron (OND, supplied by Qilu Pharmaceutical Company) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy." | 5.08 | [Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy]. ( Xu, B; Zhou, A; Zhou, J, 1997) |
| "A group of 48 patients with breast cancer were randomized in a double-blind fashion to receive either (1) granisetron as a 0." | 5.08 | Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. ( Bolwell, B; Boparai, N; Jones, E; Kalaycio, M; Mendez, Z; Overmoyer, B; Pohlman, B, 1998) |
| "A double-blind randomized crossover trial was performed to compare the antiemetic efficacy of two 5-HT3 receptor antagonists, granisetron and ondansetron, in Chinese patients receiving adjuvant chemotherapy (cyclophosphamide, methotrexate and 5-fluorouracil) for breast cancer." | 5.08 | Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study. ( Chow, LW; Poon, RT, 1998) |
| "The anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting was studied in a randomized cross-over trial in 52 patients." | 5.07 | [Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial]. ( Zeng, WY, 1992) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "Inhibitory effects on acute nausea and emesis, safety and usefulness of a single oral dose of Ondansetron tablet were evaluated in 3 different dose levels for comparison by telephone registration system, in patients receiving non-platinum anti-cancer drugs." | 5.07 | [Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "We assessed the antiemetic efficacy and safety of three different oral doses of ondansetron (GR 38032F), a novel serotonin type-3 receptor antagonist, in three consecutive series of 20 breast cancer patients receiving cyclophosphamide-doxorubicin-based chemotherapy for the first time." | 5.07 | Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. ( Ciociola, A; Esparza, L; Fraschini, G; Holmes, FA; Hortobagyi, GN; Templeton, D; Walters, RS, 1991) |
| "Anti-emetic effects, safety and usefulness of Ondansetron given intravenously at 4 mg once daily for consecutive 3-5 days were investigated against nausea and emesis induced by non-platinum anticancer drugs." | 5.07 | [Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Nukariya, N; Ohta, J; Ota, K; Taguchi, T; Tsukagoshi, S, 1992) |
| "Ondansetron was compared with metoclopramide for antiemetic efficacy in a randomised double-blind trial in 122 patients with advanced breast cancer." | 5.07 | Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. ( Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B, 1991) |
| "The efficacy of the serotonin antagonist ondansetron (GR 38032F) was evaluated in the prevention of nausea and vomiting induced by CMF chemotherapy in 29 breast cancer patients." | 5.07 | Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient. ( Campora, E; Cetto, GL; Fosser, V; Mammoliti, S; Marangolo, M; Oliva, C; Rosso, R, 1991) |
| "We examined the anti-emetic effect, safety and usefulness of ondansetron hydrochloride, a selective 5-HT3 receptor antagonist, given orally once daily at the dosage of 4 mg, for 3 to 5 consecutive days to patients with nausea and emesis induced by non-platinum anti-cancer drugs such as cyclophosphamide, doxorubicin and carboplatin." | 5.07 | [Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs]. ( Akasaka, Y; Ariyoshi, Y; Furue, H; Ikeda, M; Niitani, H; Ohta, J; Ota, K; Suminaga, M; Taguchi, T; Tsukagoshi, S, 1992) |
| "We evaluated the efficacy and safety of oral ondansetron, a selective antagonist of 5-HT3 receptors, for the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy (> 500 mg/m2)." | 5.07 | Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group. ( Burton, G; Ciociola, AA; Cubeddu, LX; Galvin, D; Meshad, M; Pendergrass, K; Ryan, T; York, M, 1994) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 5.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| " In this randomized, double-blind, placebo-controlled study, we evaluated the effect of serotonin S3 receptor blockade with ondansetron (GR 38032F) on the prevention of nausea and vomiting induced by cyclophosphamide-containing chemotherapy." | 5.06 | Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. ( Cubeddu, LX; Finn, AL; Fuenmayor, NT; Hoffman, IS, 1990) |
| "40 patients with metastatic breast cancer, under treatment with epirubicin (greater than 50 mg/m2) and cyclophosphamide (greater than 500 mg/m2), had an antiemetic therapy with Ondansetron 3 x 8 mg day, for a maximum of 10 cycles." | 5.06 | [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron]. ( Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA, 1990) |
| "The patient completed the remainder of the radiation treatment with no further emesis and minimal nausea, representing the first documented success of granisetron and aprepitant for RINV after failure on ondansetron." | 3.81 | Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report. ( Chow, E; DeAngelis, C; Hunyh, L; McDonald, R; Pasetka, M; Raman, S; Rowbottom, L, 2015) |
| "Ondansetron was superior to placebo in Study 1; complete control of emesis (0 emetic episodes) over 15 days was achieved in 62% of ondansetron-treated patients compared to 34% of placebo-treated patients (P = 0." | 3.77 | Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. ( Marschner, N, 1991) |
| "116 consecutive patients scheduled for breast cancer surgery were prospectively scored according to pain, PONV and sedation after being introduced to a combined evidence-based, empiric multimodal opioid-sparing prevention and treatment regime consisting of Paracetamol, Celecoxib, Dextromethorphan, Gabapetin, Dexamethason and Ondansetron." | 3.74 | [Multimodal treatment of pain and nausea in breast cancer surgery]. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2008) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 3.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 3.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "We investigated the prophylactic antiemetic effect of added low-dose infusion of propofol in patients exhibiting nausea and vomiting refractory to dexamethasone and serotonin antagonist during non-cisplatin chemotherapy for breast cancer." | 3.69 | Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer. ( Borgeat, A; Forni, M; Suter, PM; Wilder-Smith, O, 1994) |
| "Of 200 consecutive breast cancer patients, 191 received the full package." | 2.75 | Multimodal prevention of pain, nausea and vomiting after breast cancer surgery. ( Callesen, T; Gärtner, R; Kehlet, H; Kroman, N, 2010) |
| "as prophylaxis in breast cancer patients regimens was studied." | 2.71 | Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide. ( Coop, AJ; Dempsey, CL; Eberhardt, DR; Farley, PA; O'Briant, S; Shillington, A, 2004) |
| "Ondansetron was administered as 8 mg bid, metopimazine as 30 mg qid, and prednisolone as 50 mg qd." | 2.70 | Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. ( Dombernowsky, P; Handberg, J; Herrstedt, J; Kjaer, M; Sigsgaard, T, 2001) |
| "Ondansetron alone was not adequate to provide sustained control of CT-induced nausea and vomiting over the entire 5-day study period." | 2.69 | An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. ( Cohen, L; Davidson, T; Dix, SP; Joyce, R; Lynn, M; Miyahara, T; Osowski, CL; Sexauer, MC; Wingard, JR; Yeager, A, 1998) |
| "198 chemonaive patients with breast cancer, treated with a moderately emetogenic chemotherapy, were randomly assigned to receive either oral granisetron 1 mg twice a day on day 1, followed by metoclopramide, 60 mg on day 2 and 3, or ondansetron, 8 mg IV on day 1, followed by ondansetron 8 mg tablet twice a day on day 2 and 3." | 2.69 | [Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron]. ( Granisétron, PK; Mabro, M, 1999) |
| "Sixty chemotherapy-naive breast cancer patients of 30 to 71 years in age, P." | 2.68 | Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy. ( Ionta, MT; Massidda, B, 1996) |
| "A total of 259 chemotherapy-naive breast cancer patients treated with a 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC) regimen were randomly assigned to ondansetron (OND) 8 mg tablet or alizapride (ALI) 150 mg intravenous (i." | 2.68 | Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group. ( Bonneterre, J; Clavel, M; d'Allens, H; Paillarse, JM, 1995) |
| "Ondansetron was superior to metoclopramide for the control of emesis." | 2.68 | [The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial]. ( Zeng, W; Zhang, P; Zhou, J, 1995) |
| " Patients received an intravenous dose of 16 mg dexamethasone with either 8 mg ondansetron or 60 mg metoclopramide before chemotherapy, followed by oral dosing with 8 mg ondansetron or 20 mg metoclopramide 3 times daily for 5 days." | 2.67 | Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. ( Cassidy, J; Coleman, R; Hunter, E; Kaye, S; Kerr, D; Khanna, S; McQuade, B; Smyth, J; Soukop, M; Stewart, A, 1992) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| "Women with breast cancer without previous chemotherapy were eligible for this prospective study." | 1.35 | Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy. ( Bani, MR; Beckmann, MW; Engel, J; Fasching, PA; Kollmannsberger, B; Kreis, H; Lausen, B; Lux, MP; Niesler, B; Strick, R; Strissel, PL; Weihbrecht, S, 2008) |
| "Case 3, a 44-year-old woman, having breast cancer treated with 5-fluorouracil, cyclophosphamide, and epirubicin developed an MPR after the second chemotherapy treatment." | 1.35 | Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs. ( Barbaud, A; Bursztejn, AC; Cuny, JF; Schmutz, JL; Tréchot, P, 2008) |
| "PONV was found in 27 of 47 patients completing the study." | 1.33 | Blood-borne factors possibly associated with post-operative nausea and vomiting: an explorative study in women after breast cancer surgery. ( Bjellerup, P; Eksborg, S; Helander, A; Lindahl, S; Lönnqvist, P; Oddby-Muhrbeck, E, 2005) |
| "A group of 90 breast cancer patients undergoing chemotherapy were assessed prospectively to estimate the prevalence of acute (post-treatment) and anticipatory emesis in the 1990s." | 1.29 | Acute and anticipatory emesis in breast cancer patients. ( Casado, A; Diaz-Rubio, E; Fernández-Marcos, A; López Martin, JA; Martín, M; Rodriguez-Lescure, A; Sanchez, JJ, 1996) |
| "Ondansetron was given intravenously at a dose of 8 mg, and venous blood samples were drawn at 0, 20, 60 and 120 min." | 1.29 | Ondansetron does not stimulate prolactin release in breast cancer patients. ( Barni, S; Cazzaniga, M; Lissoni, P; Mainini, E; Rovelli, F; Tancini, G, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.22) | 18.7374 |
| 1990's | 47 (57.32) | 18.2507 |
| 2000's | 21 (25.61) | 29.6817 |
| 2010's | 12 (14.63) | 24.3611 |
| 2020's | 1 (1.22) | 2.80 |
| Authors | Studies |
|---|---|
| Tienchaiananda, P | 1 |
| Nipondhkit, W | 1 |
| Maneenil, K | 1 |
| Sa-Nguansai, S | 1 |
| Payapwattanawong, S | 1 |
| Laohavinij, S | 1 |
| Maneechavakajorn, J | 1 |
| Yeo, W | 2 |
| Lau, TK | 1 |
| Li, L | 1 |
| Lai, KT | 1 |
| Pang, E | 1 |
| Cheung, M | 1 |
| Chan, VT | 1 |
| Wong, A | 1 |
| Soo, WM | 1 |
| Yeung, VT | 1 |
| Tse, T | 1 |
| Lam, DC | 1 |
| Yeung, EW | 1 |
| Ng, KP | 1 |
| Tang, NL | 1 |
| Tong, M | 1 |
| Suen, JJ | 2 |
| Mo, FK | 2 |
| Cortés-Flores, AO | 1 |
| Jiménez-Tornero, J | 1 |
| Morgan-Villela, G | 1 |
| Delgado-Gómez, M | 1 |
| Zuloaga-Fernández Del Valle, CJ | 1 |
| García-Rentería, J | 1 |
| Rendón-Félix, J | 1 |
| Fuentes-Orozco, C | 1 |
| Macías-Amezcua, MD | 1 |
| Ambriz-González, G | 1 |
| Alvarez-Villaseñor, AS | 1 |
| Urias-Valdez, D | 1 |
| Chavez-Tostado, M | 1 |
| Contreras-Hernández, GI | 1 |
| González-Ojeda, A | 1 |
| Wenzell, CM | 1 |
| Berger, MJ | 1 |
| Blazer, MA | 1 |
| Crawford, BS | 1 |
| Griffith, NL | 1 |
| Wesolowski, R | 1 |
| Lustberg, MB | 1 |
| Phillips, GS | 1 |
| Ramaswamy, B | 1 |
| Mrozek, E | 1 |
| Flynn, JM | 1 |
| Shapiro, CL | 1 |
| Layman, RM | 1 |
| Rowbottom, L | 1 |
| Pasetka, M | 1 |
| McDonald, R | 1 |
| Hunyh, L | 1 |
| Raman, S | 1 |
| DeAngelis, C | 1 |
| Chow, E | 1 |
| Li, ZH | 1 |
| Liu, D | 1 |
| He, ZJ | 1 |
| Fan, ZY | 1 |
| Dranitsaris, G | 2 |
| Mazzarello, S | 2 |
| Smith, S | 2 |
| Vandermeer, L | 2 |
| Bouganim, N | 2 |
| Clemons, M | 2 |
| Segal, R | 1 |
| Dent, S | 1 |
| Gertler, S | 1 |
| Song, X | 1 |
| Wheatley-Price, P | 1 |
| Thamlikitkul, L | 1 |
| Srimuninnimit, V | 1 |
| Akewanlop, C | 1 |
| Ithimakin, S | 1 |
| Techawathanawanna, S | 1 |
| Korphaisarn, K | 1 |
| Chantharasamee, J | 1 |
| Danchaivijitr, P | 1 |
| Soparattanapaisarn, N | 1 |
| Gärtner, R | 3 |
| Callesen, T | 3 |
| Kroman, N | 3 |
| Kehlet, H | 3 |
| Herrstedt, J | 4 |
| Apornwirat, W | 1 |
| Shaharyar, A | 1 |
| Aziz, Z | 1 |
| Roila, F | 1 |
| Van Belle, S | 1 |
| Russo, MW | 1 |
| Levin, J | 1 |
| Ranganathan, S | 1 |
| Guckert, M | 1 |
| Grunberg, SM | 2 |
| Warr, DG | 2 |
| Street, JC | 1 |
| Carides, AD | 1 |
| Hayashi, T | 1 |
| Ikesue, H | 1 |
| Esaki, T | 1 |
| Fukazawa, M | 1 |
| Abe, M | 1 |
| Ohno, S | 1 |
| Tomizawa, T | 1 |
| Oishi, R | 1 |
| Oddby-Muhrbeck, E | 3 |
| Öbrink, E | 1 |
| Eksborg, S | 3 |
| Rotstein, S | 1 |
| Lönnqvist, PA | 2 |
| Sprung, J | 1 |
| Choudhry, FM | 1 |
| Hall, BA | 1 |
| Wattwil, M | 1 |
| Thörn, SE | 1 |
| Lövqvist, A | 1 |
| Wattwil, L | 1 |
| Gupta, A | 1 |
| Liljegren, G | 1 |
| Dempsey, CL | 1 |
| Coop, AJ | 1 |
| Shillington, A | 1 |
| Farley, PA | 1 |
| Eberhardt, DR | 1 |
| O'Briant, S | 1 |
| Gan, TJ | 1 |
| Jiao, KR | 1 |
| Zenn, M | 1 |
| Georgiade, G | 1 |
| Dua, N | 1 |
| Bhatnagar, S | 1 |
| Mishra, S | 1 |
| Singhal, AK | 1 |
| Hesketh, PJ | 1 |
| Gralla, RJ | 1 |
| Muss, HB | 1 |
| Eisenberg, PD | 1 |
| Raftopoulos, H | 1 |
| Gabriel, M | 1 |
| Rodgers, A | 1 |
| Bohidar, N | 1 |
| Klinger, G | 1 |
| Hustad, CM | 1 |
| Horgan, KJ | 1 |
| Skobieranda, F | 1 |
| Lindley, C | 1 |
| Goodin, S | 1 |
| McCune, J | 1 |
| Kane, M | 1 |
| Amamoo, MA | 1 |
| Shord, S | 1 |
| Pham, T | 1 |
| Yowell, S | 1 |
| Laliberte, K | 1 |
| Schell, M | 1 |
| Bernard, S | 1 |
| Socinski, MA | 1 |
| Helander, A | 1 |
| Bjellerup, P | 1 |
| Lindahl, S | 1 |
| Lönnqvist, P | 1 |
| Ho, WM | 1 |
| Chan, SL | 1 |
| Lau, W | 1 |
| Koh, J | 1 |
| Yeung, WK | 1 |
| Kwan, WH | 1 |
| Lee, KK | 1 |
| Mok, TS | 1 |
| Poon, AN | 1 |
| Lam, KC | 1 |
| Hui, EK | 1 |
| Zee, B | 1 |
| Fasching, PA | 1 |
| Kollmannsberger, B | 1 |
| Strissel, PL | 1 |
| Niesler, B | 1 |
| Engel, J | 1 |
| Kreis, H | 1 |
| Lux, MP | 1 |
| Weihbrecht, S | 1 |
| Lausen, B | 1 |
| Bani, MR | 1 |
| Beckmann, MW | 1 |
| Strick, R | 1 |
| Bursztejn, AC | 1 |
| Tréchot, P | 1 |
| Cuny, JF | 1 |
| Schmutz, JL | 1 |
| Barbaud, A | 1 |
| Cole, RM | 1 |
| Robinson, F | 1 |
| Harvey, L | 1 |
| Trethowan, K | 1 |
| Murdoch, V | 1 |
| Zeng, W | 1 |
| Zhou, J | 3 |
| Zhang, P | 1 |
| Framarino dei Malatesta, M | 2 |
| Veneziano, M | 2 |
| Fiorelli, C | 2 |
| Bandiera, AF | 2 |
| Yacoub, M | 1 |
| Toccaceli Blasi, MR | 1 |
| Marzetti, L | 1 |
| Galati, M | 1 |
| Paolucci, A | 1 |
| Clavel, M | 1 |
| Bonneterre, J | 4 |
| d'Allens, H | 1 |
| Paillarse, JM | 1 |
| Hebbar, M | 1 |
| Hecquet, B | 1 |
| Vanlemmens, L | 1 |
| Lecomte, S | 1 |
| Pion, JM | 1 |
| Adenis, A | 1 |
| Borgeat, A | 1 |
| Wilder-Smith, O | 1 |
| Forni, M | 1 |
| Suter, PM | 1 |
| Lissoni, P | 1 |
| Cazzaniga, M | 1 |
| Rovelli, F | 1 |
| Mainini, E | 1 |
| Tancini, G | 1 |
| Barni, S | 1 |
| Cubeddu, LX | 2 |
| Pendergrass, K | 1 |
| Ryan, T | 1 |
| York, M | 1 |
| Burton, G | 1 |
| Meshad, M | 1 |
| Galvin, D | 1 |
| Ciociola, AA | 1 |
| Buser, KS | 1 |
| Joss, RA | 1 |
| Piquet, D | 1 |
| Aapro, MS | 1 |
| Cavalli, F | 1 |
| Haefliger, JM | 1 |
| Jungi, WF | 1 |
| Bauer, J | 1 |
| Obrist, R | 1 |
| Brunner, KW | 1 |
| Sigsgaard, T | 2 |
| Boesgaard, M | 1 |
| Jensen, TP | 1 |
| Dombernowsky, P | 2 |
| Levitt, M | 1 |
| Warr, D | 1 |
| Yelle, L | 1 |
| Rayner, HL | 1 |
| Lofters, WS | 1 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Latreille, J | 1 |
| Potvin, M | 1 |
| Warner, E | 1 |
| al-Moundhri, M | 1 |
| Ezzie, J | 1 |
| Ward, R | 1 |
| Barrenetxea, G | 1 |
| Schneider, J | 1 |
| Centeno, MM | 1 |
| Romero, H | 1 |
| de la Rica, M | 1 |
| Rodríguez-Escudero, FJ | 1 |
| Massidda, B | 1 |
| Ionta, MT | 1 |
| Quigley, C | 1 |
| Bosnjak, SM | 2 |
| Neskovic-Konstantinovic, ZB | 2 |
| Jovanovic-Micic, DJ | 1 |
| Mitrovic, LB | 1 |
| Radulovic, SS | 2 |
| Fernández-Marcos, A | 1 |
| Martín, M | 1 |
| Sanchez, JJ | 1 |
| Rodriguez-Lescure, A | 1 |
| Casado, A | 1 |
| López Martin, JA | 1 |
| Diaz-Rubio, E | 1 |
| du Bois, A | 1 |
| Vach, W | 1 |
| Holy, R | 1 |
| Kriesinger-Schröder, H | 1 |
| Barreca, T | 1 |
| Corsini, G | 1 |
| Cataldi, A | 1 |
| Garibaldi, A | 1 |
| Cianciosi, P | 1 |
| Rolandi, E | 1 |
| Franceschini, R | 1 |
| Coiffier, B | 1 |
| Khayat, D | 1 |
| Misset, JL | 1 |
| Votan, B | 1 |
| Shinohara, H | 1 |
| Yonekawa, H | 1 |
| Machimura, T | 1 |
| Furukawa, T | 1 |
| Nishihori, H | 1 |
| Kurihara, N | 1 |
| Urakami, H | 1 |
| Nemoto, Y | 1 |
| Poon, RT | 1 |
| Chow, LW | 1 |
| Kalaycio, M | 1 |
| Mendez, Z | 1 |
| Pohlman, B | 1 |
| Overmoyer, B | 1 |
| Boparai, N | 1 |
| Jones, E | 1 |
| Bolwell, B | 1 |
| Gilbert, CJ | 1 |
| Petros, WP | 1 |
| Vredenburgh, J | 1 |
| Hussein, A | 1 |
| Ross, M | 1 |
| Rubin, P | 1 |
| Fehdrau, R | 1 |
| Cavanaugh, C | 1 |
| Berry, D | 1 |
| McKinstry, C | 1 |
| Peters, WP | 1 |
| Osowski, CL | 1 |
| Dix, SP | 1 |
| Lynn, M | 1 |
| Davidson, T | 1 |
| Cohen, L | 1 |
| Miyahara, T | 1 |
| Sexauer, MC | 1 |
| Joyce, R | 1 |
| Yeager, A | 1 |
| Wingard, JR | 1 |
| Mabro, M | 1 |
| Granisétron, PK | 1 |
| Sadhasivam, S | 1 |
| Saxena, A | 1 |
| Kathirvel, S | 1 |
| Kannan, TR | 1 |
| Trikha, A | 1 |
| Mohan, V | 1 |
| Lachaine, J | 1 |
| Laurier, C | 1 |
| Langleben, A | 1 |
| Vaillant, L | 1 |
| Sasaki, K | 1 |
| Yanagida, T | 1 |
| Ohya, M | 1 |
| Ishikawa, H | 1 |
| Harousseau, JL | 1 |
| Zittoun, R | 1 |
| Hedouin, M | 1 |
| Ouvry, J | 1 |
| Xu, B | 2 |
| Zhou, A | 2 |
| Huang, J | 1 |
| Wang, Z | 1 |
| Zhou, L | 1 |
| Susnjar, S | 1 |
| Mitrovi, LB | 1 |
| Sharma, A | 1 |
| Raina, V | 1 |
| Handberg, J | 1 |
| Kjaer, M | 1 |
| Bergendahl, HT | 1 |
| Muhrbeck, O | 1 |
| Ishida, T | 1 |
| Kusaba, T | 1 |
| Hayakawa, H | 1 |
| Nicholson, S | 1 |
| Evans, C | 1 |
| Mansi, J | 1 |
| Nukariya, N | 2 |
| Niitani, H | 3 |
| Taguchi, T | 3 |
| Furue, H | 3 |
| Ota, K | 3 |
| Tsukagoshi, S | 3 |
| Ariyoshi, Y | 3 |
| Ikeda, M | 3 |
| Akasaka, Y | 3 |
| Ohta, J | 3 |
| Suminaga, M | 1 |
| Soukop, M | 1 |
| McQuade, B | 1 |
| Hunter, E | 1 |
| Stewart, A | 1 |
| Kaye, S | 1 |
| Cassidy, J | 1 |
| Kerr, D | 1 |
| Khanna, S | 1 |
| Smyth, J | 1 |
| Coleman, R | 1 |
| Zeng, WY | 1 |
| De Wet, M | 1 |
| Jooste, R | 1 |
| Coccia-Portugal, MA | 1 |
| Falkson, G | 1 |
| Fraschini, G | 1 |
| Ciociola, A | 1 |
| Esparza, L | 1 |
| Templeton, D | 1 |
| Holmes, FA | 1 |
| Walters, RS | 1 |
| Hortobagyi, GN | 1 |
| Marschner, N | 1 |
| Marschner, NW | 2 |
| Adler, M | 2 |
| Nagel, GA | 2 |
| Christmann, D | 1 |
| Fenzl, E | 1 |
| Upadhyaya, B | 1 |
| Campora, E | 1 |
| Oliva, C | 1 |
| Mammoliti, S | 1 |
| Cetto, GL | 1 |
| Fosser, V | 1 |
| Marangolo, M | 1 |
| Rosso, R | 1 |
| Chevallier, B | 1 |
| Metz, R | 1 |
| Fargeot, P | 1 |
| Pujade-Lauraine, E | 1 |
| Spielmann, M | 1 |
| Tubiana-Hulin, M | 1 |
| Paes, D | 1 |
| Bons, J | 1 |
| Hoffman, IS | 1 |
| Fuenmayor, NT | 1 |
| Finn, AL | 1 |
| Jaenicke, F | 1 |
| Albrecht, U | 1 |
| Cunningham, D | 1 |
| Hawthorn, J | 1 |
| Pople, A | 1 |
| Gazet, JC | 1 |
| Ford, HT | 1 |
| Challoner, T | 1 |
| Coombes, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Phase IV Trial of Individualized Care Versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. The EPIC Study[NCT01913990] | Phase 4 | 323 participants (Anticipated) | Interventional | 2011-09-30 | Active, not recruiting | ||
| Evaluation of the Impact of the HLNatural, Inc. Immune Support Product in Reducing the Length of Cold Symptoms in Adults Suffering From the Common Cold[NCT04103099] | 200 participants (Actual) | Interventional | 2019-10-16 | Completed | |||
| A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist Casopitant (GW679769) in Combination With Ondansetron a[NCT00366834] | Phase 3 | 1,840 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Combined General Anesthesia Plus Paravertebral Block Versus General Anesthesia Plus Opioid Analgesia for Breast Cancer Surgery: A Prospective Randomized Trial[NCT01904266] | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | |||
| Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study[NCT04875559] | 236 participants (Actual) | Observational [Patient Registry] | 2021-04-19 | Completed | |||
| The Effect of Electroacustimulation on Postoperative Nausea, Vomiting and Pain in Outpatient Plastic Surgery Patients: A Prospective, Randomized, Blinded Clinical Trial[NCT00941005] | 122 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Is Intra-operative Acupuncture Point P6 Stimulation as Effective as Traditional Pharmacotherapy in Reducing Nausea and Vomiting During Cesarean Section With Regional Anesthesia?[NCT02959840] | Phase 4 | 180 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Open-label Extension to: A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With [NCT00092196] | Phase 3 | 820 participants (Actual) | Interventional | 2002-12-01 | Completed | ||
| A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Che[NCT00092183] | Phase 4 | 866 participants (Actual) | Interventional | 2002-10-10 | Completed | ||
| Aprepitant in the Prevention of Delayed Emesis Induced by Moderately Emetogenic Chemotherapy (Cyclophosphamide Plus Anthracyclines) in Breast Cancer Patients: a Double-blind Randomized Study[NCT00869973] | Phase 3 | 580 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to We terminated the study after enrolling 580/900 patients due to a slow accrual) | ||
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy[NCT01980160] | 0 participants (Actual) | Interventional | 2013-11-30 | Withdrawn (stopped due to Did not receive IRB approval from our institution therefore the study was closed.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00941005)
Timeframe: 24 hours
| Intervention | incidence of emetic events (Mean) |
|---|---|
| Electroacustimulation | 0 |
| Control | 0 |
Phone survey of post-op pain medication usage was administered on postoperative day 1. (NCT00941005)
Timeframe: 24 hours post-op
| Intervention | Participants (Count of Participants) |
|---|---|
| Electroacustimulation | NA |
| Control | NA |
(NCT00941005)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Electroacustimulation | NA |
| Control | NA |
Phone survey of nausea/vomiting symptoms was administered on postoperative day 1. The survey consists of 8 questions, including: 1) a query about whether or not participant has experienced nausea since returning home; 2) rate nausea severity on a scale of 1-10 (where 10 is the most severe); 3) a query about satisfaction of nausea control; 4) a question asking if they would use the same post-op nausea treatment again; 5) a query about what activities the participant has been unable to do since surgery; 6) whether or not the participant has taken prescription medicine for treatment of nausea since returning home; 7) whether or not participant has taken prescription medicine for treatment of pain since returning home; and 8) if yes for 6-7, which medications. (NCT00941005)
Timeframe: 24 hours post-op
| Intervention | score on a scale (Mean) |
|---|---|
| Electroacustimulation | NA |
| Control | NA |
(NCT00941005)
Timeframe: 24 hours
| Intervention | minutes (Mean) |
|---|---|
| Electroacustimulation | NA |
| Control | NA |
Nausea is scored on a scale of 1-10 where 1 is least nauseated and 10 is severely nauseated. Nausea scores will be collected 30, 60, and 120 minutes after surgery. (NCT00941005)
Timeframe: 24 hours
| Intervention | participants (Number) | ||
|---|---|---|---|
| 30 min post-op | 60 min post-op | 120 min post-op | |
| Control | NA | NA | NA |
| Electroacustimulation | NA | NA | NA |
Participants will evaluate their postoperative pain score on a scale of 1-10 where 1 is the least pain and 10 is the most severe pain. Pain scores will be evaluated at 30, 60, and 120 minutes postop. (NCT00941005)
Timeframe: 24 hours
| Intervention | score on a scale (Mean) | ||
|---|---|---|---|
| 30 min post-op | 60 min post-op | 120 min post-op | |
| Control | NA | NA | NA |
| Electroacustimulation | NA | NA | NA |
The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea at any point during the surgical procedure in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 44 |
| Metoclopramide, Ondansetron | 14 |
| Acupressure Point P6 Stimulator | 22 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage I. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 33 |
| Metoclopramide, Ondansetron | 7 |
| Acupressure Point P6 Stimulator | 14 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage II. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 12 |
| Metoclopramide, Ondansetron | 6 |
| Acupressure Point P6 Stimulator | 5 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage III. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 16 |
| Metoclopramide, Ondansetron | 8 |
| Acupressure Point P6 Stimulator | 14 |
Patients offer their subjective assessments of the level of nausea on a scale of 0-10 (0 = no nausea, 10 = worst nausea ever experienced) during stage IV. The investigators will analyze if there is a statistically significant difference between the number of patients that experience nausea in each group at this point. Patients that report nausea (1 or more on our scale) will be recorded as that they have experienced nausea. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 3 |
| Metoclopramide, Ondansetron | 4 |
| Acupressure Point P6 Stimulator | 0 |
Patients are asked their overall anesthetic care satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 53 |
| Metoclopramide, Ondansetron | 58 |
| Acupressure Point P6 Stimulator | 56 |
Patients are asked their anti-emetic treatment satisfaction (0 = Not Satisfied, 10 = Extremely Satisfied). Data are expressed as number of parturients who gave a score of 8 or higher. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 49 |
| Metoclopramide, Ondansetron | 58 |
| Acupressure Point P6 Stimulator | 55 |
The investigators will perform objective assessments of whether or not the patients have vomited during the procedure. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 27 |
| Metoclopramide, Ondansetron | 10 |
| Acupressure Point P6 Stimulator | 8 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage I. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 20 |
| Metoclopramide, Ondansetron | 5 |
| Acupressure Point P6 Stimulator | 4 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage II. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 10 |
| Metoclopramide, Ondansetron | 1 |
| Acupressure Point P6 Stimulator | 3 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage III. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 9 |
| Metoclopramide, Ondansetron | 4 |
| Acupressure Point P6 Stimulator | 6 |
The investigators will perform objective assessments of whether or not the patients have vomited during stage IV. The investigators will then analyze if there is a statistically significant difference between the number of patients that vomit in each group. (NCT02959840)
Timeframe: During the surgical procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 0 |
| Metoclopramide, Ondansetron | 2 |
| Acupressure Point P6 Stimulator | 0 |
2 reviews available for ondansetron and Breast Cancer
| Article | Year |
|---|---|
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
56 trials available for ondansetron and Breast Cancer
| Article | Year |
|---|---|
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 2019 |
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2020 |
Effects of preoperative dexamethasone on postoperative pain, nausea, vomiting and respiratory function in women undergoing conservative breast surgery for cancer: Results of a controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Analgesics, Opioid; Antiemetics; Breast Neoplasms; Dexamethasone; Doubl | 2018 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplas | 2013 |
[Influence of dexamethasone on the incidence of postoperative nausea and vomiting in breast cancer patients with neoadjuvant chemotherapy].
Topics: Adolescent; Adult; Anesthesia, General; Anesthesia, Intravenous; Anesthetics, Intravenous; Antiemeti | 2015 |
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female | 2016 |
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzodiaze | 2016 |
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Ov | 2017 |
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Administration, Oral; Alopecia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Brea | 2009 |
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Breast Ne | 2011 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Multimodal prevention of pain, nausea and vomiting after breast cancer surgery.
Topics: Acetaminophen; Aged; Amines; Analgesics, Non-Narcotic; Anesthesia Recovery Period; Anesthesia, Intra | 2010 |
Dexamethasone is as effective as ondansetron for the prevention of postoperative nausea and vomiting following breast surgery.
Topics: Adolescent; Adult; Aged; Antiemetics; Breast; Breast Neoplasms; Dexamethasone; Female; Humans; Middl | 2003 |
Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cancer Care Facilities; Cohort Studies; | 2004 |
A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting.
Topics: Adult; Aged; Analgesia; Antiemetics; Breast Neoplasms; Electroacupuncture; Female; Humans; Middle Ag | 2004 |
A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting.
Topics: Adult; Aged; Analgesia; Antiemetics; Breast Neoplasms; Electroacupuncture; Female; Humans; Middle Ag | 2004 |
A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting.
Topics: Adult; Aged; Analgesia; Antiemetics; Breast Neoplasms; Electroacupuncture; Female; Humans; Middle Ag | 2004 |
A randomized controlled comparison of electro-acupoint stimulation or ondansetron versus placebo for the prevention of postoperative nausea and vomiting.
Topics: Adult; Aged; Analgesia; Antiemetics; Breast Neoplasms; Electroacupuncture; Female; Humans; Middle Ag | 2004 |
Granisetron and ondansetron for prevention of nausea and vomiting in patients undergoing modified radical mastectomy.
Topics: Adult; Aged; Analysis of Variance; Anesthesia, General; Breast Neoplasms; Chi-Square Distribution; D | 2004 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cy | 2005 |
Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2005 |
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Carcinoma, Ductal, Br | 2009 |
[The role of ondansetron (Qilu) in the prevention of non-cisplatin-induced vomiting--a randomized clinical trial].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1995 |
Ondansetron in chemotherapy-induced emesis. Our experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female; Genital Neoplas | 1995 |
Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients. French Ondansetron Study Group.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 1994 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1993 |
Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Chemotherapy, Adjuvant; Double-Blind Method; Female; Hum | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1996 |
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cost-Benef | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplast | 1996 |
[Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Dru | 1997 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1998 |
Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemothe | 1998 |
Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bre | 1998 |
Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin | 1998 |
An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation.
Topics: Adult; Antiemetics; Antineoplastic Agents; Bone Marrow Transplantation; Breast Neoplasms; Drug Admin | 1998 |
[Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study Group of Granisetron].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Drug Therapy, Combination; Female; | 1999 |
The safety and efficacy of prophylactic ondansetron in patients undergoing modified radical mastectomy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind M | 1999 |
[Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination].
Topics: Adult; Antiemetics; Breast Neoplasms; Double-Blind Method; Drug Therapy, Combination; Female; Hemato | 2000 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by non-cisplatin chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1997 |
[Phase III clinical studies with ondansetron (Qilu) in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Child; Child, Prescho | 1997 |
[A randomized trial of Zudan in the prophylaxis of nausea and vomiting induced by cisplatin].
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Female; Humans; | 1998 |
High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemoth | 2000 |
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Drug Therapy | 2001 |
Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery.
Topics: Adrenergic alpha-Agonists; Aged; Anesthesia, General; Antiemetics; Blood Pressure; Breast Neoplasms; | 2002 |
[Examination of anti-emetic effect, safety and usefulness of single oral dose of ondansetron tablet in nausea and emesis induced by anti-cancer drugs--dose-finding study of ondansetron tablet in patients receiving non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1992 |
[Examination of anti-emetic effect and safety of multiple intravenous doses of ondansetron in patients receiving nonplatinum anti-cancer drugs].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas | 1992 |
[Examination of inhibitory effect, safety and usefulness of SN-307 (ondansetron) administered orally once daily for 3-5 consecutive days on nausea and emesis associated with non-platinum anti-cancer drugs].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents | 1992 |
Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Dexamethasone; Drug Tolerance; Female; | 1992 |
[Anti-emetic effect of ondansetron in cisplatin induced nausea and vomiting--a randomized clinical trial].
Topics: Adult; Aged; Antiemetics; Breast Neoplasms; Cisplatin; Female; Humans; Lung Neoplasms; Male; Melanom | 1992 |
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Topics: Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1991 |
Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Im | 1991 |
Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1991 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 1990 |
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dou | 1990 |
26 other studies available for ondansetron and Breast Cancer
| Article | Year |
|---|---|
Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Topics: Antiemetics; Aprepitant; Bone Neoplasms; Breast Neoplasms; Female; Granisetron; Humans; Middle Aged; | 2015 |
[Postoperative inconveniences after breast cancer surgery].
Topics: Acetaminophen; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasms; Celecoxib; Cyc | 2008 |
[Multimodal treatment of pain and nausea in breast cancer surgery].
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Antiemetics; Antitussive Agents; Breast Neoplasm | 2008 |
Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2012 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
Extrapyramidal reactions to ondansetron: cross-reactivity between ondansetron and prochlorperazine?
Topics: Adult; Antiemetics; Basal Ganglia Diseases; Breast Neoplasms; Cross Reactions; Female; Humans; Maste | 2003 |
Blood-borne factors possibly associated with post-operative nausea and vomiting: an explorative study in women after breast cancer surgery.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Inhalation; Anesthetics, Inhalation; Antiemetics; Blood | 2005 |
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Epirubicin | 2008 |
Cutaneous adverse drug reactions during chemotherapy: consider non-antineoplastic drugs.
Topics: Adult; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cross Reactions; Drug Eruptions; Female | 2008 |
Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
Topics: Analgesics; Bone Neoplasms; Breast Neoplasms; Drug Therapy, Combination; Female; Haloperidol; Humans | 1994 |
Ondansetron-induced headache. Our experience in gynecological cancer.
Topics: Breast Neoplasms; Female; Genital Neoplasms, Female; Headache; Humans; Migraine Disorders; Ondansetr | 1995 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
Adjuvant propofol enables better control of nausea and emesis secondary to chemotherapy for breast cancer.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Appetite; Breast Neoplasms; Consc | 1994 |
Ondansetron does not stimulate prolactin release in breast cancer patients.
Topics: Adult; Breast Neoplasms; Female; Humans; Middle Aged; Ondansetron; Prolactin | 1994 |
Rectal administration of ondansetron in uncontrolled emesis induced by chemotherapy.
Topics: Administration, Rectal; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 1995 |
5HT3 receptor antagonists and pruritus due to cholestasis.
Topics: Aged; Breast Neoplasms; Cholestasis; Female; Granisetron; Humans; Liver Neoplasms; Ondansetron; Prur | 1996 |
Acute and anticipatory emesis in breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; | 1996 |
Effect of the 5-HT3 receptor antagonist ondansetron on plasma AVP secretion: a study in cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Arginine Vasopressin; Br | 1996 |
Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer.
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Canada; Cost-Benefit Analysis; Humans; Metoclo | 1999 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
Generalised seizures following ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epi | 2001 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |
[Tasks in the care of breast neoplasms].
Topics: Breast Neoplasms; Humans; Ondansetron | 1992 |
Ondansetron in intractable nausea and vomiting.
Topics: Adult; Antiemetics; Bone Neoplasms; Breast Neoplasms; Female; Humans; Imidazoles; Nausea; Ondansetro | 1992 |
Ondansetron in a patient with porphyria.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Ondansetron; Porphyrias | 1992 |
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Imidazoles; Injections, Intravenous; Lympho | 1987 |